SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 30.07 |
| Enterprise Value ($M) | 57.46 |
| Book Value ($M) | -0.06 |
| Book Value / Share | -0.01 |
| Price / Book | -477.34 |
| NCAV ($M) | -8.47 |
| NCAV / Share | -1.52 |
| Price / NCAV | -3.55 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.71 |
| Return on Assets (ROA) | -0.49 |
| Return on Equity (ROE) | -1.98 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 5.90 |
| Current Ratio | 5.90 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 27.03 |
| Assets | 35.44 |
| Liabilities | 35.51 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.33 |
| Operating Income | -22.16 |
| Net Income | -20.89 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -18.02 |
| Cash from Investing | 10.58 |
| Cash from Financing | 8.84 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Shayna LP | 8.10 | ||
| 13G/A | Slager David Mark | 6.70 | 21.95 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 50,075 | 120,616 | 41.52 | |
| 49,499 | 119,541 | 41.41 | |
| 5,261 | 17,693 | 29.73 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| PDSB – PDS Biotechnology Corporation | PHIO – Phio Pharmaceuticals Corp. |
| PIRS – Pieris Pharmaceuticals, Inc. | PMCB – PharmaCyte Biotech, Inc. |
| PMN – ProMIS Neurosciences, Inc. |
Financial data and stock pages provided by
Fintel.io